Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.

Appleyard, Maria Virginia C L

Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. [electronic resource] - International journal of cancer Jan 2009 - 465-72 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1097-0215

10.1002/ijc.23938 doi


Animals
Antineoplastic Agents--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Breast Neoplasms--drug therapy
Cell Line, Tumor
Cyclin-Dependent Kinase Inhibitor p27--metabolism
Cyclin-Dependent Kinases--metabolism
Doxorubicin--administration & dosage
Drug Synergism
Female
Humans
Mammary Neoplasms, Animal--drug therapy
Mice
Mice, Nude
Neoplasm Transplantation
Protein Kinase Inhibitors--administration & dosage
Purines--administration & dosage
Roscovitine